Skip to main content

Advertisement

SpringerLink
Log in

Bladder paragangliomas: a pictorial review

  • Review
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Bladder paragangliomas (bPGL) are rare neuroendocrine tumors arising from the sympathetic paraganglia present in the bladder wall. Bladder PGLs are typically submucosal or intramural but when subserosal may not be readily visible at cystoscopy. The average size at presentation is 3.9 cm (range 1.0–9.1 cm). When small, bPGL are usually spherical, well-marginated and homogeneous. Larger bPGL are typically more complex with peri- and intra-tumoral neovascularity and central necrosis. On ultrasound, increased color Doppler signal is typical. The increased soft tissue resolution of MRI enables localization of bPGL within the bladder wall more accurately than CT. Restricted diffusion and avid contrast enhancement help differentiate small bPGLs from leiomyomas, which have similar appearances on ultrasound and CT. Nuclear medicine techniques identify bPGLs and their metastases with high specificity, 68Ga-DOTATATE PET/CT having largely replaced 123I-mIBG SPECT/CT as the first line functional investigation. Imaging is essential to aid surgical planning, as endoscopic resection is often not possible or incomplete due to tumor location. For patients with advanced disease, 68Ga-DOTATATE PET/CT and 123I-mIBG SPECT/CT assess suitability for peptide receptor radionuclide therapy. Up to 63% of bPGL patients have a germline mutation, most commonly in the SDHB subunit gene, increasing their risk of developing pheochromocytomas and further paragangliomas; lifelong annual biochemical and periodic imaging screening from skull base to pelvis is therefore recommended.

Graphical abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

References

  1. Purnell S, Sidana A, Maruf M, Grant C, Agarwal PK (2017) Genitourinary paraganglioma: Demographic, pathologic, and clinical characteristics in the surveillance, epidemiology, and end results database (2000-2012). Urol Oncol 35:457.e459-457.e414

    Article  Google Scholar 

  2. Lenders JWM, Kerstens MN, Amar L et al (2020) Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 38:1443-1456

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Beilan JA, Lawton A, Hajdenberg J, Rosser CJ (2013) Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature. BMC Urol 13:22

    Article  PubMed  PubMed Central  Google Scholar 

  4. Zhai H, Ma X, Nie W et al (2017) Paraganglioma of the Urinary Bladder: A Series of 22 Cases in a Single Center. Clin Genitourin Cancer 15:e765-e771

    Article  PubMed  Google Scholar 

  5. Martucci VL, Lorenzo ZG, Weintraub M et al (2015) Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol 33:167.e113-120

    Article  Google Scholar 

  6. Plouin PF, Amar L, Dekkers OM et al (2016) European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. Eur J Endocrinol 174:G1-g10

    Article  CAS  PubMed  Google Scholar 

  7. Lu H, Male M, Jiang K, Ye Z, Song D, Xia D (2019) Clinical significance of functional and anatomical classifications in paraganglioma of the urinary bladder. Urol Oncol 37:354.e359-354.e317

    Article  Google Scholar 

  8. Ranaweera M, Chung E (2014) Bladder paraganglioma: A report of case series and critical review of current literature. World journal of clinical cases 2:591-595

    Article  PubMed  PubMed Central  Google Scholar 

  9. Male M, Ye T, Tao J, Chen Z-Q, Peng E (2019) Differentiating Nonfunctional Paraganglioma of the Bladder from Urothelial Carcinoma of the Bladder: Pitfalls and Breakthroughs. BioMed research international 2019:1097149-1097149

    Article  PubMed  PubMed Central  Google Scholar 

  10. Qin J, Zhou G, Chen X (2020) Imaging manifestations of bladder paraganglioma. Ann Palliat Med 9:346-351

    Article  PubMed  Google Scholar 

  11. Liang J, Li H,Gao L, Yin L, Yin L, Zhang J (2016) Bladder Paraganglioma: Clinicopathology and Magnetic Resonance Imaging Study of Five Patients. Urol J 13:2605-2611

    PubMed  Google Scholar 

  12. Fan DG, Wu CL, Huang HJ et al (2020) [Paraganglioma of urinary bladder: a clinicopathological features analysis of 23 cases]. Zhonghua Bing Li Xue Za Zhi 49:311-316

    CAS  PubMed  Google Scholar 

  13. Wang H, Ye H, Guo A et al (2011) Bladder paraganglioma in adults: MR appearance in four patients. Eur J Radiol 80:e217-220

    Article  PubMed  Google Scholar 

  14. Wang EY, Pak JS, Virk RK et al (2020) Bladder Preservation for Patients With Bladder Paragangliomas: Case Series and Review of the Literature. Urology 143:194-205

    Article  PubMed  Google Scholar 

  15. Withey SJ, Perrio S, Christodoulou D et al (2019) Imaging Features of Succinate Dehydrogenase–deficient Pheochromocytoma-Paraganglioma Syndromes. RadioGraphics 39:1393-1410

    Article  PubMed  Google Scholar 

  16. Chang Y-K, Chiang IN, Chen C-H et al (2015) Paragangliomas of the urinary bladder: A report of 6 cases and review of the literature. Urological Science 26:111-114

    Article  Google Scholar 

  17. Li Y, Guo A, Tang J et al (2014) Evaluation of sonographic features for patients with urinary bladder paraganglioma: a comparison with patients with urothelial carcinoma. Ultrasound Med Biol 40:478-484

    Article  CAS  PubMed  Google Scholar 

  18. Huang L, Kong Q, Liu Z, Wang J, Kang Z, Zhu Y (2018) The Diagnostic Value of MR Imaging in Differentiating T Staging of Bladder Cancer: A Meta-Analysis. Radiology 286:502-511

    Article  PubMed  Google Scholar 

  19. Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2017) Diagnostic performance of MRI for prediction of muscle-invasiveness of bladder cancer: A systematic review and meta-analysis. Eur J Radiol 95:46-55

    Article  PubMed  Google Scholar 

  20. Jacques AE, Sahdev A, Sandrasagara M et al (2008) Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol 18:2885-2892

    Article  PubMed  Google Scholar 

  21. Moran CA, Albores-Saavedra J, Wenig BM, Mena H (1997) Pigmented extraadrenal paragangliomas. A clinicopathologic and immunohistochemical study of five cases. Cancer 79:398-402

    Article  CAS  PubMed  Google Scholar 

  22. Mou JW, Lee KH, Tam YH, Cheung ST, Chan KW, Thakre A (2008) Urinary bladder pheochromocytoma, an extremely rare tumor in children: case report and review of the literature. Pediatr Surg Int 24:479-480

    Article  CAS  PubMed  Google Scholar 

  23. Chen M, Lipson SA, Hricak H (1997) MR imaging evaluation of benign mesenchymal tumors of the urinary bladder. American Journal of Roentgenology 168:399-403

    Article  CAS  PubMed  Google Scholar 

  24. Wong-You–Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA (2006) Neoplasms of the Urinary Bladder: Radiologic-Pathologic Correlation. RadioGraphics 26:553-580

    Article  Google Scholar 

  25. Chung AD, Schieda N, Flood TA et al (2015) Suburothelial and extrinsic lesions of the urinary bladder: radiologic and pathologic features with emphasis on MR imaging. Abdom Imaging 40:2573-2588

    Article  PubMed  Google Scholar 

  26. Kim JC, Kim KH, Jung S (2003) Small cell carcinoma of the urinary bladder: CT and MR imaging findings. Korean journal of radiology 4:130-135

    Article  PubMed  PubMed Central  Google Scholar 

  27. Parra LA, Swanson SK, Salomao MA, Yang M (2020) Multifocal Urinary Bladder Paragangliomas With Negative 68Ga-DOTATATE Uptake and Positive 123I-MIBG Uptake. Clin Nucl Med 45:e156-e157

    Article  PubMed  Google Scholar 

  28. Maurice JB, Troke R, Win Z et al (2012) A comparison of the performance of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 39:1266-1270

    Article  CAS  PubMed  Google Scholar 

  29. Moses WW (2011) Fundamental Limits of Spatial Resolution in PET. Nuclear instruments & methods in physics research Section A, Accelerators, spectrometers, detectors and associated equipment 648 Supplement 1:S236-S240

    Article  CAS  Google Scholar 

  30. Khalil MM, Tremoleda JL, Bayomy TB, Gsell W (2011) Molecular SPECT Imaging: An Overview. International Journal of Molecular Imaging 2011:796025

  31. Bhatia KS, Ismail MM, Sahdev A et al (2008) 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf) 69:181-188

    Article  Google Scholar 

  32. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP (2008) 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med 49:1232-1237

    Article  PubMed  Google Scholar 

  33. Janssen I, Blanchet EM, Adams K et al (2015) Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res 21:3888-3895

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. King K, Chen C, Alexopoulos D et al (2011) Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-d-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy. Journal of Clinical Endocrinology and Metabolism 96:2779-2785

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wittekind C, Brierley J, Lee A, van Eycken E (2019) TNM Supplement: A Commentary on Uniform Use, 5th Edition edn. Wiley-Blackwell

  36. Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons

    Google Scholar 

  37. Lloyd R, De Lellis R, Heitz P, Eng C (2004) World Health Organization classification of tumours: pathology and genetics of tumours of the endocrine organs. International Agency for Research on Cancer (IARC) Press, Lyon

  38. Srirangalingam U, Banerjee A, Patki P et al (2017) Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas. Clin Genitourin Cancer 15:e131-e136

    Article  PubMed  Google Scholar 

  39. Fliedner SMJ, Lehnert H, Pacak K (2010) Metastatic paraganglioma. Seminars in oncology 37:627-637

    Article  PubMed  PubMed Central  Google Scholar 

  40. Cheng L, Leibovich BC, Cheville JC et al (2000) Paraganglioma of the urinary bladder. Cancer 88:844-852

    Article  CAS  PubMed  Google Scholar 

  41. Ayala-Ramirez M, Feng L, Johnson MM et al (2011) Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 96:717-725

    Article  CAS  PubMed  Google Scholar 

  42. Vanderveen KA, Thompson SM, Callstrom MR et al (2009) Biopsy of pheochromocytomas and paragangliomas: potential for disaster. Surgery 146:1158-1166

    Article  PubMed  Google Scholar 

  43. Sanjoaquín MT, Fraile JR, Gutiérrez A, Canal MI, Navia J (2000) Hypertensive crisis during a transurethral resection of the bladder: nondiagnosed bladder paraganglioma. Anesth Analg 90:556-558

    Article  PubMed  Google Scholar 

  44. Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K (2010) The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39:775-783

    Article  PubMed  PubMed Central  Google Scholar 

  45. Wang C, Richmond R, Eldesouki E (2015) Anesthetic management for resection of para-aortic paraganglioma and unexpected aortic resection: A case report. Exp Ther Med 9:1542-1544

    Article  PubMed  PubMed Central  Google Scholar 

  46. García MIDO, Palasí R, Gómez RC, Marco JLP, Merino-Torres JF (2019) Surgical and pharmacological management of functioning pheochromocytoma and paraganglioma. Exon Publications:63–80

  47. Niemeijer ND, Alblas G, van Hulsteijn LT, Dekkers OM, Corssmit EP (2014) Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin Endocrinol (Oxf) 81:642-651

    Article  CAS  Google Scholar 

  48. Nastos K, Cheung VTF, Toumpanakis C et al (2017) Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. J Surg Oncol 115:425-434

    Article  CAS  PubMed  Google Scholar 

  49. Gimenez-Roqueplo AP, Dahia PL, Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44:328-333

    Article  CAS  PubMed  Google Scholar 

  50. Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine 17:405-423

    Article  PubMed  PubMed Central  Google Scholar 

  51. Ellard S, Baple EL, Berry I et al (2019) ACGS Best Practice Guidelines for Variant Classification 2019,

  52. Lenders JWM, Duh Q-Y, Eisenhofer G et al (2014) Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism 99:1915-1942

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Guy’s and St Thomas’ NHS Foundation Trust, Westminster Bridge Road, London, SE1 7EH, UK

    Samuel J. Withey, Dimitra Christodoulou, Davide Prezzi, Giles Rottenberg, Cherry Sit & Audrey E. T. Jacques

  2. Department of Nuclear Medicine, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Cherry Sit & Fahim Ul-Hassan

  3. Department of Endocrinology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Paul Carroll & Anand Velusamy

  4. Department of Genetics, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Louise Izatt

  5. Department of Urology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK

    Rajesh Nair

Authors
  1. Samuel J. Withey
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dimitra Christodoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Davide Prezzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giles Rottenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cherry Sit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fahim Ul-Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paul Carroll
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Anand Velusamy
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Louise Izatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Rajesh Nair
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Audrey E. T. Jacques
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel J. Withey.

Ethics declarations

Conflict of interest

The authors declare no funding and no conflicts of interest. No patient-identifiable information is used in the manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Withey, S.J., Christodoulou, D., Prezzi, D. et al. Bladder paragangliomas: a pictorial review. Abdom Radiol 47, 1414–1424 (2022). https://doi.org/10.1007/s00261-022-03443-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-022-03443-2

Keywords

Search

Navigation